Search PubMed⌕ Search

SEARCH · Search PubMed

Results for “Histocompatibility”

Search indexed PubMed citations on genomics, clinical trials, systematic reviews and public health. Explore titles, authors and supplied subject terms, then open the PubMed record.

Quote a phrase for an exact phrase match. Source license links do not imply unrestricted reuse.

At least 181 records · Page 10Linked to original sources

Minor but not major histocompatibility antigens of thymus epithelium tolerize precursors of cytolytic T cells.

Treatment of fetal thymuses with 2-deoxyguanosine depletes these organs of many haematopoietic cells, and if such thymuses are transplanted into allogeneic athymic nude mice, intrathymic development of cytolytic T-lymphocyte precursors (CTL-P) occurs, including those which are specific for class I major histocompatibility complex (MHC) antigens expressed by the thymus epithelium. Thus, T cells from BALB/c (H-2d) nude mice transplanted with allogeneic C57BL/6 (H-2b) thymic epithelium can be stimulated in vitro to produce CTL specific for H-2b class I MHC antigens. We report here that thymocytes and lymph node T cells from such mice are responsive in mixed leukocyte reaction in the absence of exogenous growth factors, indicating that lack of tolerance is manifest at the level of CTL-P and proliferating T cells. We also show that T cells from such mice are tolerant to minor histocompatibility antigens of the thymus donor in the context of MHC antigens of the recipient. The results indicate that haematopoietic rather than epithelial cells tolerize CTL-P and that donor-type minor but not major histocompatability antigens can be presented in tolerogenic form by haematopoietic cells expressing recipient-type MHC antigens.

Animals↗

HA-1 and the SMCY-derived peptide FIDSYICQV (H-Y) are immunodominant minor histocompatibility antigens after bone marrow transplantation.

BACKGROUND: Allogeneic bone marrow donors can be incompatible at different levels. Even HLA-identical pairs will be still incompatible for numerous minor histocompatibility antigens (mHag). Nevertheless, some incompatibilities are found to be associated with an increased risk of graft-versus-host disease (GVHD), which could be related to the way the immune system recognizes these antigens. METHODS: We determined the specificity of cytotoxic T-cell clones isolated during acute GVHD or during bone marrow graft rejection in patients (n=14) transplanted with marrow from donors who were histoincompatible for different minor and/or major histocompatibility antigens. RESULTS: We found a clear hierarchy among the different types of histoincompatibilities. In three combinations mismatched for a class I allele, all 27 clones isolated during GVHD were specific for the incompatible HLA molecule. In the 11 class I-identical combinations, 14 different mHags were recognized. The mHag HA-1, known to have a significant impact on the development of GVHD, was recognized in the two HA-1-incompatible combinations. In one of these combinations, which was sex mismatched, all 56 clones analyzed were directed against HA-1, demonstrating the dominance of this mHag. In the four HA-1-compatible, sex-mismatched combinations, the anti-H-Y response was directed against one immunodominant epitope rather than against multiple Y-chromosome-encoded epitopes. All male specific cytotoxic T lymphocytes (n=15) recognized the same high-performance liquid chromatography-purified peptide fraction presented by T2 cells. Moreover, all cytotoxic T lymphocytes tested (n=6) were specific for the SMCY-derived peptide FIDSYICQV, originally described as being the H-Y epitope recognized in the context of HLA-A*0201. CONCLUSIONS: Some histocompatibility antigens are recognized in an immunodominant fashion and will therefore be recognized in the majority of mismatched combinations. Only for such antigens, correlations between mismatches and the occurrence of GVHD or graft rejections will be found.

Bone Marrow Transplantation↗

Histocompatible embryonic stem cells by parthenogenesis.

Genetically matched pluripotent embryonic stem (ES) cells generated via nuclear transfer or parthenogenesis (pES cells) are a potential source of histocompatible cells and tissues for transplantation. After parthenogenetic activation of murine oocytes and interruption of meiosis I or II, we isolated and genotyped pES cells and characterized those that carried the full complement of major histocompatibility complex (MHC) antigens of the oocyte donor. Differentiated tissues from these pES cells engrafted in immunocompetent MHC-matched mouse recipients, demonstrating that selected pES cells can serve as a source of histocompatible tissues for transplantation.

Animals↗

Murine streptozotocin diabetes: influences of the major histocompatibility complex, genetic background and blood transfusion.

Major histocompatibility complex-linked immune response genes are thought to influence susceptibility to induction of both human insulin-dependent diabetes and murine streptozotocin-induced diabetes. To clarify this relationship, we administered streptozotocin intravenously in two doses (120 and 240 mg/kg body weight) on days 0 and 14, and monitored blood glucose until day 100 in young adult male mice of differing background genome and/or H-2 complex. In addition, we examined the effect of allogeneic whole blood transfusion on subsequent susceptibility to diabetes. B10 recombinant mice possessing the k allele at the centromeric H-2-K and I-A loci were most susceptible to diabetes induction. Variation in susceptibility of different inbred strains with the same major histocompatibility complex genotype suggested a rôle for non-major histocompatibility complex genes. Blood transfusion delayed the onset, but did not significantly reduce the incidence of, delayed hyperglycaemia. We conclude that, in this murine model, multiple genes within the outside the major histocompatibility complex influence multiple-dose streptozotocin-diabetes susceptibility, and that prior blood transfusion may modulate diabetes induction.

Animals↗

Expression of class I histocompatibility antigens on human T-B lymphoblast hybrids.

Expression of class I histocompatibility antigens (HLA-A and B) on hybrids of human T and B lymphoblastoid cell lines (LCL) was examined. The T-LCL CEM expressed low levels of HLA-A and B antigens. CEMR and CEMR .3, two 8-azaguanine- and ouabain-resistant sublines of CEM used for fusion, expressed no detectable HLA-B antigens and expressed HLA-A antigens at a level below that of CEM. The three B-LCL studied expressed class I histocompatibility antigens at levels 50- to 80-fold in excess of that found on CEM as assessed by indirect immunofluorescence and flow cytometry. Total levels of class I histocompatibility antigens on hybrids of CEMR and CEMR .3 with B-LCL were similar to those found on the B-LCL. CEM-encoded HLA-A and B antigens were expressed on the hybrids at levels much greater than those seen on CEM itself; expression by the hybrids of CEM-encoded and B-LCL-encoded class I antigens was comparable. By RNA-DNA filter hybridization, CEMR .3 was found to have extremely low levels of class I heavy-chain mRNA compared with two B-LCL and with HSB, a T-LCL that expresses high levels of class I histocompatibility antigens. Thus, the paucity of HLA-A and B expression by CEMR .3 (and by inference, CEMR and CEM), as well as the enhancement of CEM-encoded HLA-A and B antigen expression on B-LCL X T-LCL hybrids, must be due, at least in part, to modulation of the level of transcripts encoding HLA class I heavy chains.

Antibodies, Monoclonal↗

Impact of histocompatibility antigens on pregnancy outcome.

OBJECTIVE: The role of histocompatibility antigens in pregnancy outcome is controversial. This controversy may be because the initial studies were of small numbers or the patient groups were not homogeneous. The purpose of this study is to clarify these discrepant results by carrying out histocompatibility antigen typing and mixed lymphocyte culture on couples with idiopathic recurrent spontaneous abortion and by comparing results with those of fertile couples. STUDY DESIGN: Sixty couples with at least three spontaneous abortions and 60 normal couples with at least two successful pregnancies were included. Histocompatibility antigen typing and mixed lymphocyte culture were performed by using the standard techniques. The data were analyzed statistically with the Fisher exact test and chi 2. RESULTS: Our results failed to show any difference between normal and aborting couples with regard to HLA-A, HLA-B, and HLA-DR distribution or sharing or to mixed lymphocyte culture responsiveness. CONCLUSION: Our study, along with other studies, emphasizes that the histocompatibility antigen system does not have an impact on pregnancy outcome.

Abortion, Habitual↗

Control of expression of histocompatibility antigens (H-2) and beta 2-microglobulin in F9 teratocarcinoma stem cells.

Murine teratocarcinoma stem cells, unlike most other cell types, do not express major histocompatibility antigens. The steady-state levels of beta 2-microglobulin and H-2 mRNA from F9-derived teratocarcinoma stem and differentiated cells were examined by blot hybridization using cloned DNA probes specific for these mRNAs. No H-2- or beta 2-microglobulin-specific RNA was detected in F9 teratocarcinoma stem cells (clone 12-1); thus, F9 teratocarcinoma stem cells (clone 12-1) contain no more than 1/10 the H-2 and beta 2-microglobulin mRNAs of the differentiated daughter cells (clone 12-1a). We suggest that this regulation of major histocompatibility antigen expression is due to transcriptional control of the major histocompatibility antigen genes, H-2 and beta 2-microglobulin. The transcriptional regulation of these genes is accompanied by a change in their DNase I sensitivity. Normally, transcriptionally inactive genes are DNase I resistant, while active genes are DNase I sensitive. In contrast, the silent major histocompatibility antigen genes of teratocarcinoma stem cells are more DNase I sensitive than the active genes of the differentiated cells.

Beta-Globulins↗

Direct evaluation of antigen binding to human T lymphocyte clones: involvement of major histocompatibility complex products in antigen binding.

Cloned human helper T lymphocytes reactive with a defined peptide (p20; residues 306-329) of the HA-1 molecule of influenza virus hemagglutinin were analyzed for their capacity to specifically bind peptide antigen. Three different methods of analyzing antigen binding to T cell receptors were compared. One method involved the binding of radiolabeled T cells to antigen-pulsed populations of sheep erythrocyte rosette-negative (E-) cells (B cells and monocytes). The binding was antigen specific, in that only E- cells pulsed with the appropriate antigen bound the treated T cells, and was inhibitable by free peptide. Furthermore, antigen binding was major histocompatibility complex-restricted in that only E- cells histocompatible at the HLA-D region locus bound the T cells, and monoclonal antibody of the relevant specificity was able to inhibit the binding. Secondly, it was demonstrated that tritiated T cells could bind to insolubilized antigen (p20) in the absence of E- cells. The binding was inhibited by anti-class II antibody suggesting that the interaction of antigen with the T cells involves recognition of T cell major histocompatibility complex class II determinants. Finally, radiolabeled peptides were also used to detect binding to the appropriate clones in the absence of presenting cells. This binding was specific, inhibitable by the appropriate unlabeled peptide and temperature dependent. These studies demonstrate that the process of antigen binding to receptors is analyzable and should in turn facilitate the analysis of the mechanism of T cell activation.

Antigen-Presenting Cells↗

Systemic immune response to peripheral nerve transplants across major histocompatibility class-I and class-II barriers.

The use of peripheral nerve transplantation in limb reconstruction has been limited by tissue rejection. In order to identify the major histocompatibility antigens involved in tissue rejection, mutant strains of inbred mice, differing from the parent strain (C57BL/6) by either major histocompatibility complex Class I (B6.C-H2bml mice) or Class II (B6.C-H2bml2 mice), were used in models of nerve transplantation. One, 2, and 3 weeks after nerve or skin transplantation, the immune response in the recipient animal was monitored with use of lymphocyte-dependent cytotoxicity and complement-dependent cytotoxicity assays. Skin transplants were used for comparison as the gold standard of a nonvascularized graft with an easily observable success or failure. There was no significant cellular immune response by the lymphocyte-mediated cytotoxicity assay when nerve or skin transplants involved an isolated Class-I or Class-II mismatch, but there was a significant response 2 weeks after transplantations across a combined Class-I and Class-II barrier for nerve (p < 0.04) or skin (p < 0.03). An antibody response to the grafts occurred for both skin and nerve transplants but only when a combined barrier was involved. This preliminary study, using a mouse model, suggests that nerve transplantation-may be performed without systemic evidence of rejection with only a partial cross match of the major histocompatibility complexes, thus decreasing the complexity of tissue typing necessary for tissue banking.

Animals↗

Impaired expression of chimaeric major histocompatibility complex transgenes associated with plasmid sequences.

Plasmid vector sequences were retained (vector+), or removed (vector-) from hybrid major histocompatibility complex gene constructs prior to microinjection of fertilized ova for the production of transgenic mice. In transgenic mice containing integrated vector+ gene constructs, low levels of class II cell surface determinants were detected on splenocytes from only two out of six independent lines. Class II membrane determinants were not detectable on splenocytes from the remaining four vector+ transgenic lines. Expression of transgene products did not correlate with transgene copy number which ranged from 1-10 copies. Low levels of mRNA transcripts were detected in thymic mRNA from vector+ lines. In contrast, high levels of thymic and splenic mRNA transcripts were detected in offspring from all four vector- transgenic lines. Spleen cells from the vector- transgenic animals also expressed high levels of the hybrid major histocompatibility complex transgene products. These results implicate plasmid vector sequences in the inhibition of expression of the hybrid class II-class I major histocompatibility complex genes in transgenic mice. This putative inhibition of transgene expression presumably occurs at the level of gene transcription.

Animals↗

Establishment of in vitro cellular model predicting histocompatibility in allograft.

A novel in vitro cellular model producting recipient-donor histocompatibility in allograft was developed to select the donor validity. Fifteen couples of blood samples of donor and recipient in human BMT were examined using the model, and skin allograft in mice was performed to test the model. The results showed that the less the differences of histocompatibility evaluated by the model were, the later GVHR in human BMT occurred and the longer the survival time of skin allografts in mice. It was suggested that the model could be used to predict correctly histocompatibility between donor and recipient.

Animals↗

Histocompatibility antigen(s) linked to Rfp-Y (Mhc-like) genes in the chicken.

Major histocompatibility complex (Mhc) genes influencing transplantation rejections were first described in mice within the H2 complex and secondly in chickens within the B complex. In chickens, Rfp-Y haplotypes have recently been identified which contain class I and class II Mhc-like genes that assort independently of the B complex. Three Rfp-Y haplotypes have been defined in a closed breeding flock of line N chickens. In this study, progeny were obtained from line N Rfp-Y heterozygous matings to establish the role of Rfp-Y in transplantation immunity. Rfp-Y incompatibility did not induce significant one-way mixed lymphocyte responses. However, Rfp-Y-incompatible skin grafts were rejected more frequently and at a faster rate than Rfp-Y-compatible grafts by two-week-old chicks. The control Mhc B-incompatible grafts were rejected faster than the Rfp-Y-incompatible grafts; the latter were rejected at speeds that resemble rejection of minor histocompatibility antigens. We conclude that Rfp-Y class I and II Mhc-like genes are linked to the expression of minor histocompatibility antigens in chickens.

Animals↗

Immunoprecipitation of insulin receptors by antibodies against Class 1 antigens of the murine H-2 major histocompatibility complex.

Insulin receptors from C57BL/6J mouse (H-2b) liver membranes were specifically labeled with 125I-photo-reactive insulin by UV irradiation. Membranes were solubilized and the capacity of various antibodies reacting with the major histocompatibility complex to immunoprecipitate insulin receptors was tested. About 5% of the labeled receptors were immunoprecipitated by a conventional mouse antiserum against H-2b histocompatibility antigens and by a monoclonal antibody against Class 1 antigens of the H-2b haplotype (Kb and Db). No immunoprecipitation was obtained with a monoclonal antibody against Class 2 antigens of I-Ab or against Class 1 antigens of the H-2k haplotype. Insulin receptors can thus be specifically immunoprecipitated by antibodies against class I histocompatibility antigens.

Animals↗

Acquired allo-tolerance to major or minor histocompatibility antigens indifferently contributes to preventing diabetes development in non-obese diabetic (NOD) mice.

Diabetes in NOD mice represents the end stage of a genetically-programmed autoimmune process mediated by T lymphocytes and directed against insulin-producing beta cells. We have shown in a previous study that the course of the disease is significantly inhibited in NOD mice which have been made tolerant at birth to foreign histocompatibility antigens. This early T cell manipulation results in a significant delay of disease onset, reduced overall incidence and less severe alterations of islet cells. In order to characterize better the nature of the foreign tolerogenic determinants responsible for this protection, we have now examined separately the contribution of MHC and non-MHC antigens. Two lines of congenic mice were used as donors of tolerogenic cells, NOD.H-2b, which differ from NOD by the MHC-encoded antigens only, and B10.H-2g7, which differ by all the minor histocompatibility antigens encoded by the B10 background, but which share with NOD mice the same MHC haplotype. Our results show that NOD recipients of F1 semi-compatible cells become specifically tolerant to the set of alloantigens to which they were neonatally exposed. Unresponsiveness, assessed by lack of CTL generation, is profound and specific. Yet, despite the fact that distinct sets of alloreactive T cell precursors are silenced, mice made tolerant indifferently to major or minor histocompatibility antigens are significantly protected against overt diabetes. These results could mean that each set of MHC and non-MHC encoded determinants can independently cross-tolerize a sufficient proportion of the autoreactive repertoire to slow the natural course of the disease. Alternatively, neonatally-acquired tolerance might induce polyclonal activation of the immune system resulting in the suppression or the immunodeviation of potentially harmful, autoreactive T cell clones.

Animals↗

Minor histocompatibility antigens: from transplantation problems to therapy of cancer.

The idea of transferring healthy marrow for the therapeutic treatment of the various diseases of the blood and of the immune system made a significant contribution to controlling diseases and to advancing modern clinical sciences. The first series of bone marrow transplantations in the 1960s were confronted with severe complications. It became clear that matching for the human leukocyte antigen (HLA) system between donor and recipient significantly improved the clinical results. Nonetheless, an unacceptable percentage of severe complications remained that is mainly attributable to non-HLA histocompatibility systems, i.e., minor histocompatibility antigens. Observations in the 1970s that minor histocompatibility antigens cause serious problems in human bone marrow transplantation laid the basis for their use as curative antigens in stem cell transplantation to date. Thus, the allo-immune T cell activities caused by minor histocompatibililty antigen disparities between HLA-matched donor and recipient can now be applied for the benefit of the transplant patient.

Bone Marrow Transplantation↗

The histocompatibility complex and rheumatic diseases.

Histocompatibility typing has assumed an increasingly important role as a clinical and research tool in rheumatic diseases. The HLA antigens which are serologically defined (A and B series) are being used most extensively for clinical work, but the role of other immunologic determinants in the HLA complex is being evaluated. These include D-locus (MLC) determinants, several complement components, and immune response genes which have been well characterized in the mouse, but not in man. The products of the major histocompatibility complex are inherited in a simple Mendelian fashion as a series of co-dominant alleles. Large population studies have characterized the frequencies of various alleles, and family studies have allowed tentative mapping of the various loci within the complex on the sixth chromosome in man. A number of diseases which are considered to be autoimmune in nature are now known to be associated with specific HLA antigens. Of these disease associations, the strongest and best studied are the seronegative spondyloarthropathies which are highly associated with the B27 antigen. Included in this group are ankylosing spondylitis, Reiter's syndrome, psoriatic arthropathy, colitic arthropathy, Yersinia arthritis and a small group of juvenile rheumatoid arthritis patients with features of ankylosing spondylitis. The clinical application of tissue typing or B27 testing is most helpful in regard to difficult diagnostic problems in patients with early or atypical seronegative spondyloarthropathy. Its value as an indicator of prognosis, and its value in counselling family members is not well established. There are many interesting hypotheses regarding pathogenetic mechanisms of these rheumatic diseases based on susceptibility factors related to the major histocompatibility complex. An abnormal immune response gene within the complex is probably a key feature of the mechanism, but the exact details are little more than speculative at this point.

Alleles↗

From peptides to peptidomimetics: design of nonpeptide ligands for major histocompatibility proteins.

The ever increasing data available on antigen presentation by class I or class II histocompatibility proteins have made these glycoproteins highly interesting pharmaceutical targets for either vaccination or immunosuppressive therapy of autoimmune diseases and cancers. Herewith, we review the design and biological properties of the very first nonpeptide ligands of major histocompatibility proteins as well as their potential application in vaccination, Major Histocompatibility Complex (MHC) blockade or T cell receptor antagonism.

Animals↗

Dog class I gene DLA-88 histocompatibility typing by PCR-SSCP and sequencing.

The dog has been an important model for solid organ and hematopoietic stem cell transplantation, as well as for studying autoimmune diseases, the growth of malignant tumors and the immunology of vaccines. Fundamental to the continuing usage of the canine model for research is the development of molecular-based histocompatibility typing. Previous histocompatibility methods have focused on class II genes. This study was undertaken to develop a molecular-based histocompatibility typing method for the most polymorphic class I gene, DLA-88. In this study, polymerase chain reaction single-stranded conformational polymorphism was used to separate alleles, thereby allowing sequenced-based typing.

Alleles↗